medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Number 4

<< Back Next >>

Ann Hepatol 2008; 7 (4)

Portopulmonary hypertension: state of the art

Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ

Language: English
References: 77
Page: 321-330
PDF size: 131.35 Kb.


Text Extraction

Portopulmonary hypertension is an uncommon but treatable pulmonary vascular consequence of portal hypertension, which can lead to significant morbidity and mortality. Portopulmonary hypertension results from excessive pulmonary vasoconstriction and vascular remodeling that eventually leads to right-heart failure and death if left untreated. Although pulmonary vascular disease in these patients may be asymptomatic or associated with subtle and nonspecific symptoms (dyspnea, fatigue and lower extremity swelling), it should be looked for especially if patients are potential candidates for liver transplantation. Patients with clinical suspicion of portopulmonary hypertension should undergo screening testing, specifically echocardiography. Right heart catheterization remains the gold standard for the diagnosis. The existence of moderate to severe disease poses higher risks and challenges for liver transplantation. The disease has a substantial impact on survival and requires focused pharmacological therapy. New and evolving medical therapies, such as prostanoids (intravenous, inhaled or oral), endothelin receptors antagonists, phosphodiesterases inhibitors, combination therapy and other experimental drugs might change the natural course of the disease. Case reports and cases series have been published regarding the efficacy and safety of pharmacological therapy, but randomized, controlled multicenter trials are urgently needed. Liver transplantation is not the treatment of choice for portopulmonary hypertension, but after optimal hemodynamic and clinical improvement with medical therapy as a bridge, liver transplant can be considered an option in selected patients.


REFERENCES

  1. Mantz FA, Craig E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. Arch Pathol Lab Med 1951; 52: 91-7.

  2. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007; 28: 203-18.

  3. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004; 24: 861-80.

  4. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-8.

  5. Swanson KL, Krowka MJ. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleve Clin J Med 2008; 75: 121-36.

  6. Passarella M, Fallon MB, Kawut SM. Portopulmonary hypertension. Clin Liver Dis 2006; 10: 653-63.

  7. McDonnell P, Toyle P, Hutchins G. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437-41.

  8. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003; 123: 562-76.

  9. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, Cortese DA, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clinic Proc 1996; 71: 543-51.

  10. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494-500.

  11. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splachnic hemodynamics. Gastroenterology 1991; 100: 520-8.

  12. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196-203.

  13. Herve P, Lebrec D, Brenot F, Simmoneau G, Humbert F, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153-66.

  14. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascitis. Gut 2003; 52: 1355-62.

  15. Bernardi M, Gulberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL. Plasma endothelin-1 and 3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol 1996; 24: 161-8.

  16. Flemale A, Sabot JP, Popjin M, Procureur M, Urbain G, Dierckx JP, Delmes JP. Pulmonary hypertension associated with portal hypertension. Eur J Respir Dis 1985; 66: 224-8.

  17. Tilg H, Wilmer A, Vogel W. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.

  18. Kereveu A, Callebert J Humbert M. High plasma serotonin levels in primary pulmonary hypertension. Arterioscler Thromb Vasc Biol 2000; 20: 2233-9.

  19. Beaudry P, Hadangue A, Callbert J. Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis. Hepatology 1994; 20: 800-3.

  20. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-32.

  21. Porres-Aguilar M, Anaya-Ayala JE, Porres-Munoz M, Bracamontes F. Chronic thromboembolic pulmonary hypertension. Cir Cir 2007; 75: 131-8.

  22. Krowka MJ. Pulmonary hypertension. Mayo Clin Proc 2000; 75: 625-30.

  23. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ, Johnson LB. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999; 67: 1087-93.

  24. Swanson KL, Krowka MJ. Arterial oxygenation associated with portopulmonary hypertension. Chest 2002; 121: 1869-75.

  25. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation; a prospective study. Hepatology 2003 ;37: 401-9.

  26. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-32.

  27. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Weisner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-50.

  28. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, Weisner RH. Accuray of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000; 6: 453-8.

  29. Krowka MJ, Swanson KI, Frantz RP, McGoon MD, Wiesner R. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44: 1502-10.

  30. Krowka MJ. Portopulmonary hypertension: diagnostic advances and caveats. Liver Transpl 2003; 9: 1336-7.

  31. Krowka MJ. Pulmonary hypertension: diagnostics and therapeutics. Mayo Clin Proc 2000; 75: 625-30.

  32. Porres-Aguilar M, Porres-Munoz M. Progress in the pharmacological management of pulmonary arterial hypertension. Med Int Mex 2004; 20: 208-20.

  33. Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S. Hemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002; 20: 1314-31.

  34. Krowka MJ, Edwards WD. A spectrum of pulmonary vascular pathology in portopulmonary hypertension. Liver Transpl 2000; 6: 2421-2.

  35. Halank M, Ewert R, Seyfarth HJ, Hoeffken G. Portopulmonary hypertension. J Gastroenterol 2006; 41: 837-47.

  36. Hoeper MM, Rubin LJ. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med 2006; 173; 499-505.

  37. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-31.

  38. Ota K, Shijo H, Kokawa H, Kubara K, Kim T, Akiyoshi N, Yokoyama M, et al. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol 1995; 10: 198-204.

  39. Navasa M, Bosch J, Reichen J, Bru C, Mastai R, Zysset T, Silva G, et al. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology 1988; 8: 850-4.

  40. Rich S, McLaughlin VV. The effects of chronic intravenous prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184-87.

  41. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Weisner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-8.

  42. Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007; 13: 875-85.

  43. Tan HP, Markowitz JS, Montgomery RA, Merritt WT, Klein AS, Thuluvath PL, Poordad FF, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001; 7: 745-9.

  44. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604-6.

  45. Swanson KL, McGoon MD, Krowka MJ. Survival in portopulmonary hypertension and orthotopic liver transplantation. Liver Transpl 2005; 11: C71.

  46. Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999; 5: 362-5.

  47. Golbin JM, Krowka MJ. Effect of prostacyclins on thrombocytopenia in portopulmonary hypertension. Data presented at the 2006 Pulmonary Hypertension Association International Conference. Minneapolis, MN. June 23-25, 2006.

  48. Benza RL, Tallaj JA, Rayburn BK, Foley BA, Bourge RC. Safety and efficacy of treprostinil in cirrhosis-related pulmonary arterial hypertension. Hepatology 2003; 38: A530.

  49. Halank M, Marx C, Usicenko S, Opitz C, Winkler J, Ewert R. Inhaled iloprost for patients with portopulmonary hypertension. Am J Respir Crit Care Med 2003; 167: A277.

  50. Minder S, Fischler M, Muellhaupt B, Zalunardo MP, Jenni R, Clavien PA, Speich R. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24: 703-7.

  51. Nagasue N, Dahr DK, Yamanoi A, Emi Y, Udagawa J, Yamamoto A, et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 2000; 31: 1107-14.

  52. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-15.

  53. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.

  54. Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Invest Drugs 2002; 11: 991-1002.

  55. Kuntzen C, Guelberg V, Gerbes AL. Use of a mixed receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128: 164-8.

  56. Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2: 1039-42.

  57. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502-8.

  58. Halank M Miehke S, Hoeffken G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77: 1775-6.

  59. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welter T, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096-1102.

  60. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan for pulmonary arterial hypertension, randomized, double blind, placebo-controlled, multicenter efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-9.

  61. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch DB, Fleming T, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.

  62. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.

  63. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004; 10: 945-50.

  64. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28: 563-7.

  65. Krowka MJ, Swanson KL. How should we treat portopulmonary hypertension. Eur Respir J 2006; 28: 466-7.

  66. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simmoneau G, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-6.

  67. Krowka MJ, Mandell MS, Ramsay MA, Kawut MS, Fallon MB, Manzarbeitia C, Pardo M Jr, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10: 174-82.

  68. DeWolf AM, Begliomini B, Gasior TA, Kang Y, Pinsky Ml. Right ventricular function during orthotopic liver transplantation. Anesthes Analges 1993; 76: 562-8.

  69. Csete M. Intraoperative management of liver transplant patients with portopulmonary hypertension. Liver Transplant Surg 1997; 3: 454-5.

  70. Acosta F, Sansano T, Palenciano CG, Domenech P, Falcon L, Robles R, Bueno FS, et al. Portopulmonary hypertension and liver transplantation: hemodynamic consequences at reperfusion. Transplant Proc 2005; 37: 3865-6.

  71. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O’Mahony C, Zhang E, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single center series. Am J Transplant 2006; 6: 177-82.

  72. Rafanan AL, Maurer J, Mehta AC, Schilz R. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000; 118: 1497-500.

  73. Mandell MS, Groves BM, Duke J. Progressive plexogenic pulmonary hypertension following liver transplantation. Transplantation 1995; 59: 1488-90.

  74. Kett DH, Acosta RC, Campos MA, Rodriguez MJ, Quartin AA, Schein RM. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 2001; 7: 645-8.

  75. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevski HI. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transplant 2005; 11: 1107-11.

  76. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, Wilson C, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 2008; 14: 287-91.

  77. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transpl 2008; 8: 1-9.




2020     |     www.medigraphic.com